Stock Analiz

Voyager Therapeutics, Inc. VYGR

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026

$1.73Market cap $108M
Open the interactive analysis →

Voyager Therapeutics, Inc. (VYGR) is a healthcare company listed in the US with a market value of about $108M. In the twelve months to September 30, 2026 it had revenue of $25M and net income of -$105M, a net margin of -416.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -25% a year, a 5-year average ROIC of -22%.

About Voyager Therapeutics

Voyager Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2015. Revenue went from $17M in 2015 to $40M in 2025, growth of about 8.8% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 334% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S4.3
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-102.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-49.5%
Revenue growth (5 yrs, per year)-25.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-125.7%
ROIC (5-yr avg.)-21.5%
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$25M$40M$80M$250M$41M$37M$171M$104M$8M$10M$14M
Net income-$105M-$120M-$65M$132M-$46M-$71M$37M-$44M-$88M-$71M-$40M
Free cash flow-$110M-$135M-$19M$75M-$15M-$55M-$109M$41M-$20M-$65M-$48M
EPS (diluted)$-1.74$-2.04$-1.13$2.97$-1.21$-1.89$0.98$-1.21$-2.75$-2.64$-1.59
Net margin-416.3%-296.5%-81.2%52.9%-113.5%-190.3%21.5%-41.8%-1158.8%-697.6%-282.6%
ROIC—-44.8%-19.2%47.0%-48.9%-41.8%10.7%-30.5%-195.7%-42.4%-24.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Voyager Therapeutics pay a dividend?

Not currently.

Is Voyager Therapeutics a good stock to buy?

We do not give buy or sell advice. Voyager Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.